Back to top

Analyst Blog

ResMed (RMD - Analyst Report) recently completed patient enrollment for the international, randomized study – SERVE-HF. The study will be conducted on 1,325 participants to assess whether treatment of central sleep-disordered breathing (central sleep apnea) can improve survival and outcomes of patients with stable heart failure.

SERVE-HF is being carried out in over 80 sites across the globe. These sites are located in Germany, Norway, Sweden, Denmark, Switzerland, Finland, France, the U.K., the Netherlands, the Czech Republic and Australia.

SERVE-HF commenced in 2008 to establish the health impact of the adequate treatment of central sleep-disordered breathing on mortality and morbidity in heart failure patients. The study is expected to round off by mid-2015. ResMed expects the results in the first half of 2016.

SERVE-HF will mainly establish whether controlling central sleep apnea in patients with Cheyne–Stokes respiration (CSA-CSR) through ResMed’s PaceWave proprietary Minute Ventilation ASV technology (found in the company’s AutoSet CS and VPAP Adapt devices) will lead to higher survival rates and reduce hospitalizations in the patient population.

According to findings, roughly 14 million Europeans suffer from heart failure. Additionally, in these patients, central sleep-disordered breathing is highly prevalent co-morbidity. Articles published in medical journals like Pulmonary Medicine, European Journal of Heart Failure and Archives of Cardiovascular Disease reveal that approximately 30%-50% of heart patients are highly prone to this co-morbid condition.

Given this backdrop, the outcome of the SERVE-HF study will have crucial impact on the treatment of these co-morbid conditions. A health economics analysis will further determine the potential economic gains from ResMed’s technology to treat CSA-CSR.

ResMed currently holds a major position in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered breathing. Favorable outcomes from this breakthrough clinical study that demonstrate the clinical efficacy of ResMed’s AutoSet CS and VPAP Adapt devices will be a major boost for the company.

Considering the market overview, there is massive growth opportunity driven by lifestyle trends, further penetration and increasing awareness. Currently, ResMed carries a Zacks Rank #3 (Hold).

While we remain on the sidelines for ResMed, other medical sector stocks like Alere Inc. (ALR - Snapshot Report), Boston Scientific Corporation (BSX - Analyst Report) and LeMaitre Vascular, Inc. (LMAT - Snapshot Report) are worth considering. Alere carries a Zacks Rank #1 (Strong Buy) whereas the other two are Zacks Rank #2 (Buy) stocks.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%